Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 12/2019

11.10.2019 | Original Article

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease

verfasst von: Tomoaki Haga, Takahiro Okumura, Satoshi Isobe, Fuji Somura, Naoaki Kano, Tasuku Kuwayama, Tsuyoshi Yokoi, Hiroaki Hiraiwa, Toru Kondo, Akinori Sawamura, Ryota Morimoto, Hiroshi Yamamoto, Kazuya Tsuboi, Toyoaki Murohara

Erschienen in: Annals of Nuclear Medicine | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Information on the relationship between myocardial damage assessed by myocardial scintigraphy and prognosis in patients with Anderson–Fabry disease (AFD) is lacking. We therefore aimed to investigate the prognostic impacts of myocardial thallium-201 (201Tl) and iodine-123 beta-methyl 15-para-iodophenyl 3(R, S)-methylpentadecanoic acid (123I-BMIPP) dual scintigraphy in patients with AFD.

Methods

Eighteen consecutive patients with AFD underwent resting myocardial 201Tl/123I-BMIPP dual scintigraphy. Total defect scores (TDS) on both images were calculated visually according to the 17-segment model using a 5-point scoring system. The mismatch score (MS) was calculated as ‘TDS on 123I-BMIPP—TDS on 201Tl’.

Results

Six major adverse cardiac events (MACEs) were recorded during a mean follow-up of 6.7 ± 4.2 years (three heart failure requiring hospitalization and three cardiac deaths). Left ventricular mass index, left atrial diameter, brain natriuretic peptide, TDS on 123I-BMIPP, and MS were all significantly greater in patients with MACEs compared with those without. Kaplan–Meier analysis indicated that high TDS on 123I-BMIPP and high MS were associated with poor event-free survival.

Conclusion

TDS on 123I-BMIPP was a better prognostic determinant in patients with AFD than TDS on 201Tl. Myocardial 201Tl/123I-BMIPP dual scintigraphy may thus be a useful noninvasive modality for evaluating prognosis in patients with AFD.
Literatur
1.
Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.CrossRef
2.
MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.CrossRef
3.
Kubo T, Ochi Y, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol. 2017;69:302–7.CrossRef
4.
O’Mahony C, Elliot P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52:326–35.CrossRef
5.
Hughes DA, Elliot PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153–8.CrossRef
6.
Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50–9.CrossRef
7.
Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972;3:289–32929.CrossRef
8.
Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, et al. Myocardial substrate utilization and left ventricular function in Adriamycin cardiomyopathy. J Nucl Med. 1993;34:1529–35.PubMed
9.
Narus H, Arii T, Kondo T, Morita M, Ohyanagi M, Iwasaki T, et al. Fatty acid imaging of stunned myocardium: clinical usefulness of iodine 123-labeled fatty acid imaging in patients with acute myocardial infarction. J Nucl Cardiol. 1998;5:275–84.CrossRef
10.
Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I–15 (p-iodophenyl)-3 (R, S) -methylpentadecanoic acid myocardial scintigraphy. Cardiology. 2000;93:43–9.CrossRef
11.
Zhao C, Shuke N, Okizaki A, Yamamoto W, Sato J, Ishikawa Y, et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cariomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med. 2003;17:541–8.CrossRef
12.
Inoue A, Fujimoto S, Yamashina S, Yamazaki J. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Ann Nucl Med. 2007;21:399–404.CrossRef
13.
Zavadovsky KV, Gulya MO, Lishmanov YB, Levedev DI. Perfusion and metabolic scintigraphy with 123I-BMIPP in prognosis of cardiac resynchronization therapy in patients with dilated cardiomyopathy. Ann Nucl Med. 2016;30:325–33.CrossRef
14.
Nanasato M, Hirayama H, Ando A, Isobe S, Nonokawa M, Kinoshita Y, et al. Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging. 2016;31:1512–21.CrossRef
15.
Tamaki N, Tadamura E, Kudoh T, Hattori N, Yonekura Y, Nohara R, et al. Prognostic value of iodine-123 labelled BMIPP fatty acid analogue imaging in patients with myocardial infarction. Eur J Nucl Med. 1996;23:272–9.CrossRef
16.
Frustaci A, Russo MA, Francone M, Chimenti C. Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy. Circulation. 2014;130:1530–1.CrossRef
17.
Zarate YA, Hopkin RJ. Lysosomal strage disease 3. Fabry’s disease. Lancet. 2008;372:1427–35.CrossRef
18.
Berman DS, Kang X, Gransar H, Gerlach J, Friedman JD, Hayes SW, et al. Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol. 2009;16(1):45–53.CrossRef
19.
Lang RM, Luigi PB, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1–39.CrossRef
20.
Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, et al. Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2016;43:729–39.CrossRef
21.
Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266–73.CrossRef
22.
Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–45.CrossRef
23.
Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, et al. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994;45:1397–400.CrossRef
24.
Amman K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–22.
25.
Nakajima K, Shimizu K, Taki J, Uetani Y, Konishi S, Tonami N, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med. 1995;36:1934–40.PubMed
26.
Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med. 1997;38:1407–11.PubMed
27.
Kawai Y, Tsukamoto E, Nozaki T, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol. 2001;38:1888–944.CrossRef
28.
Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J. 2003;24(23):2151–5.CrossRef
29.
Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24:125–35.CrossRef
30.
Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30:188–99.CrossRef
Metadaten
Titel
Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease
verfasst von
Tomoaki Haga
Takahiro Okumura
Satoshi Isobe
Fuji Somura
Naoaki Kano
Tasuku Kuwayama
Tsuyoshi Yokoi
Hiroaki Hiraiwa
Toru Kondo
Akinori Sawamura
Ryota Morimoto
Hiroshi Yamamoto
Kazuya Tsuboi
Toyoaki Murohara
Publikationsdatum
11.10.2019
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 12/2019
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-019-01406-0

Weitere Artikel der Ausgabe 12/2019

Annals of Nuclear Medicine 12/2019 Zur Ausgabe

Short Communication

Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients

Original Article

Correction of head movement by frame-to-frame image realignment for receptor imaging in positron emission tomography studies with [11C]raclopride and [11C]FLB 457

Original Article

Association between carotid 18F-NaF and 18F-FDG uptake on PET/CT with ischemic vascular brain disease on MRI in patients with carotid artery disease

Original Article

Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer

Invited Review Article

From the respective expert viewpoints of the ANM specialty editors

Original Article

PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels